A Study of Using Epigenetic Modulators to Enhance Response to MK-3475 in Microsatellite Stable Advanced Colorectal Cancer

Trial Profile

A Study of Using Epigenetic Modulators to Enhance Response to MK-3475 in Microsatellite Stable Advanced Colorectal Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Mar 2018

At a glance

  • Drugs Azacitidine (Primary) ; Pembrolizumab (Primary) ; Romidepsin (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Mar 2018 Planned End Date changed from 1 Jun 2018 to 1 Oct 2018.
    • 19 Mar 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Aug 2018.
    • 22 Jun 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top